Silver Spring, MD – Dog owners across the U.S. have a new treatment option for anxiety-related behaviors as the Food and Drug Administration approved a first-of-its-kind medication this week.
According to the FDA, Tessie (tasipimidine oral solution) is the first approved drug designed to treat both noise aversion and separation anxiety in dogs—two of the most common fear-based behavioral conditions affecting pets nationwide.
Noise aversion can be triggered by fireworks, traffic, or other loud sounds, while separation anxiety occurs when dogs are left alone. Symptoms may include barking, trembling, destructive behavior, or accidents inside the home.
The FDA said the medication works by targeting receptors in a dog’s brain to reduce heightened “fight-or-flight” responses. The drug is typically administered one hour before a known stress trigger, such as fireworks, or before leaving a dog alone.
Tessie can be given up to three times within a 24-hour period, with spacing between doses. Officials note it should not be administered with food, as that may delay absorption.
Veterinarians emphasize that behavioral training remains a key part of treatment, with medication used in more severe cases or alongside training programs.
Because proper diagnosis is required, Tessie will be available by prescription only. The drug is manufactured by Finland-based Orion Corporation.
The approval marks a significant step in veterinary medicine, offering pet owners a new tool to manage anxiety and improve quality of life for dogs experiencing stress-related conditions.
